The abstract is read at the publisher; the summary is JClub's.
In 31 patients with advanced biliary tract cancer receiving rucaparib plus nivolumab maintenance, the 4-month progression-free survival rate was 54.8% (95% CI 36–72.7), not meeting the primary target.
- Why it matters: Maintenance strategies after first-line platinum in advanced BTC are needed, especially for patients with DNA damage response or IDH1 alterations where benefit is uncertain.
- What they did: This phase II multicenter trial (NCT03639935) tested rucaparib with nivolumab in patients without progression after 4–6 months of platinum chemotherapy, using 4-month PFS as the primary endpoint.
- The result: The 4-month PFS rate was 83.3% in the DDR cohort and 100% in the IDH1 cohort, with median PFS1 4.6 months and OS1 15.9 months; grade ≥3 events included anemia (12.9%) and elevated liver enzymes (12.9%).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.